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Review paper
The Minister of Health for the UK was advised by an expert committee meeting
in February 2014 to include a new, broad-spectrum meningococcal serogroup B
(MenB) vaccine, 4CMenB (Bexsero®) into the childhood immunization pro-
gram. This new vaccine which recently received regulatory approval in Europe,
Canada and Australia combines a conventional wild-type outer membrane vesi-
cle (wtOMV) vaccine and antigens identified through reverse vaccinology.
Strain coverage estimates from different parts of the world are in the range of
70 % to 90 %, depending on the local epidemiological situation. Following im-
plementation of this vaccine, monitoring should focus on effectiveness data for
various circulating strains and potential vaccine effects on carriage and herd im-
munity. From use of this new MenB vaccine on a larger scale and good monitor-
ing in UK and other countries that are likely to follow shortly, the international
vaccine community will learn a number of lessons. Such insights will be impor-
tant for further improvement towards later generations of MenB vaccines and
other protein-based vaccines against various diseases. Herein sights gained
from more than 35 years of development and use of MenB vaccines are present-
ed. The novel vaccine, 4CMenB represents a new time horizon in protein-based
vaccine formulation, evaluation and value. Importantly, 4CMenB was devel-
oped with "cutting edge" joined with conventional vaccine technology, includ-
ing experience from previous wtOMV vaccines, which have been successfully
used since the late 1980s to prevent clonal outbreaks. Data from large clinical
studies and retrospective statistical analyses give effectiveness estimates of at
least 70 % and a consistent pattern of moderate reactogenicity during the use of
>80 million doses of three different wtOMV vaccine formulations. The key lim-
itation of these wtOMV vaccines is the immunodominant response against the
hypervariable PorA protein (especially in infants) and their likely inability to
control disease in a population where the circulating strains are highly diverse.
In New Zealand from 2004 to 2008, the wtOMV vaccine MeNZB® was used to
control a clonal MenB epidemic. This public health intervention provided a
number of new insights regarding international and public-private collabora-
tion, vaccine safety surveillance, vaccine effectiveness-estimation and commu-
nication to the public. Thus, 4CMenB marks a new paradigm and represents the
use of historical knowledge at the same time. Finally, the world now has the pos-
sibility to use a vaccine which is designed to give more comprehensive protec-
tion in epidemiological situations where circulating strains are very heterolo-
gous with respect to the genetic and antigenic properties. The historical integra-
tion of knowledge represented by 4CMenB will also prove important for other
vaccine development in the time to come.
Dug i trnovit put prema sveobuhvatnom cjepivu protiv meningokoka
grupe B
Pregledni rad
Stru~no povjerenstvo je na sastanku u velja~i 2014. godine savjetovalo ministra
zdravlja Ujedinjenog Kraljevstva da u imunizacijski program za djecu uklju~i
novo sveobuhvatno cjepivo za meningokoknu serogrupu B (MenB), 4CMenB
(Bexsero®). Ovo novo cjepivo, koje je nedavno slu`beno odobreno u Europi,
Kanadi i Australiji, kombinira konvencionalno cjepivo dobiveno iz vanjske
membrane vezikula divljeg tipa meningokoka (wtOMV) i antigene koji su iden-
tificirani kroz reverznu vakcinologiju. Procjena obuhva}enosti sojeva meningo-
koka iz razli~itih dijelova svijeta ovim cjepivom je izme|u 70 % i 90 %, ovisno
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ingly widespread. This was possible because of important
advances in technology, including the principle of using
the capsular polysaccharide as a vaccine antigen, which
was discovered and developed by Drs. Emil C. Gotschlich,
Irvin Goldschneider and colleagues at the Walter Read
Army Institute of Research, USA, in the late 1960s [23,
24]. Their efforts produced highly effective vaccines
against serogroup A and C disease. Serogroup Y and W
vaccines were developed using the same strategy, and a
quadrivalent ACYW polysaccharide vaccine was licensed
in 1981 [25, 26]. Although these relatively inexpensive
vaccines are effective, they have some important limita-
tions. They employ T-cell independent antigens, which do
not induce immunological memory, are in general not ef-
fective in children below 2 years of age and may induce
hyporesponsiveness after multiple immunizations [27–
29]. In the early 21st century, safe and effective conjugate
vaccines against serogroups A, C, Y and W were intro-
duced in a number of countries to protect all age groups by
2004 [30–34] and a low-cost conjugate vaccine against
serogroup A disease was developed for use in Africa a few
years later [15, 35, 36]. Hence, control of meningococcal
serogroup B (MenB) became the remaining challenge for
the overall prevention of meningococcal disease world-
wide [22, 30]. 
The story of vaccine development against MenB dis-
ease has been long, complicated and full of challenges [2,
3, 37, 38]. Due to molecular mimicry between the MenB
capsular structure [α(2→8)-linked N-acetylneuraminic
acid residues or polysialic acid] and glycoproteins in hu-
man tissue (especially in fetal, neural structures as, the
neural cell-adhesion molecule, N-CAM) the MenB cap-
sule is non-immunogenic [39, 40]. Should a vaccine for-
mulation successfully break this immunologic tolerance,
the scientific community and the regulators have been
afraid that it might lead to auto-immunologic damages [41,
Introduction
A vaccine against serogroup B has long been consid-
ered as part of the 'final frontier' of meningococcal disease
prevention [1–3]. Recently, a novel vaccine, 4CMenB,
was recommended by the Joint Committee of Vaccines and
Immunisation (JCVI) in the UK as an addition to the rou-
tine childhood immunization schedule [4, 5]. This article
discusses the history and lessons learned, as well as the dif-
ficulties surmounted to achieve this long sought-after goal.
Meningococcal septicemia and meningitis were feared
even before the meningococcus was identified in the early
nineteenth century [6–10]. Meningococcal infection is as-
sociated with rapid onset of severe disease, often follow-
ing initial mild unspecific symptoms, and can often result
in high case fatality rates or permanent disability. Hence
there is a high level of anxiety concerning the possibility
for epidemic disease caused by virulent clones or more
sporadic, endemic incidences, which can occur suddenly
in otherwise healthy individuals [1, 11–14]. Before the an-
tibiotic era, the mortality rate was 70–90 %, and this has re-
mained between 5 and 15 % despite the advent of modern
antibiotics and advanced intensive hospital care [5, 9, 13,
15]. Permanent disabilities affect approximately 10–20 %
of survivors [16, 17]. Case fatality rates are higher than
average in patients with septicaemia, during epidemics,
among adolescents and the elderly [18–20]. Infants and
children under five years of age are most commonly affect-
ed by invasive meningococcal disease, and adolescents are
also vulnerable to the disease especially during epidemic
waves [12, 21]. Traditionally, the seasonal outbreaks of
serogroup A disease in the Sub-Saharan "meningitis belt"
in Africa has been considered to have the most significant
global impact [22].
Starting in the late twentieth century, routine vaccina-
tion against meningococcal disease has become increas-
o lokalnoj epidemiolo{koj situaciji. Nakon provedene primjene
ovog cjepiva, treba usmjeriti promatranje na podatke o u~inkovi-
tosti za razli~ite cirkuliraju}e sojeve i potencijalne u~inke cjepi-
va na klicono{tvo i ste~eni imunitet. Dio me|unarodne zajednice
koja se bavi cjepivima nau~it }e brojne lekcije iz {ire upotrebe
ovog novog MenB cjepiva i dobrog pra}enja djelotvornosti
cjepiva u Ujedinjenom Kraljevstvu kao i ostalim zemljama koje
bi uskoro mogle slijediti ovaj primjer. Takve spoznaje bit }e
va`ne za daljnje pobolj{anje kasnijih generacija MenB cjepiva i
ostalih cjepiva protiv raznih bolesti koja se baziraju na proteini-
ma. Rad donosi nove spoznaje ste~ene tijekom 35 godina razvo-
ja i upotrebe MenB cjepiva. Novo cjepivo, 4CMenB, predstavlja
novu epohu u formulaciji, procjeni i vrijednosti cjepiva koja se
baziraju na proteinima. Zna~ajno je spomenuti da je 4CmenB
razvijeno spajanjem "cutting edge" i konvencionalne cjepne
tehnologije, uklju~uju}i iskustva od ranijih wtOMV cjepiva koja
se uspje{no koriste od 1980-ih u svrhu prevencije klonalnih epi-
demija. Podaci velikih klini~kih studija i retrospektivne sta-
tisti~ke analize daju procjenu u~inkovitosti od najmanje 70 % i
dosljedno prikazuju umjerene reaktogenosti cjepiva tijekom
uporabe od >80 milijuna doza za tri razli~ite formulacije
wtOMV cjepiva. Glavno ograni~enje ovih wtOMV cjepiva je
imunodominantni odgovor prema hipervarijabilnom PorA pro-
teinu (posebno u djece) i vjerojatna nemogu}nost da se bolest
kontrolira u populaciji gdje postoje razli~iti cirkuliraju}i sojevi.
Na Novom Zelandu je u razdoblju od 2004. do 2008. godine ko-
ri{teno wtOMV cjepivo MeNZB® kako bi se kontrolirala klo-
nalna MenB epidemija. Javnozdravstvena intervencija je pru`ila
mnogo novih spoznaja u pogledu me|unarodne i javno-privatne
suradnje, nadzora sigurnosti cjepiva, procjene u~inkovitosti
cjepiva i komunikacije s javno{}u. Stoga, 4CMenB obilje`ava
novu paradigmu i predstavlja kori{tenje povijesnog znanja
istodobno. Kona~no, svijet sada ima mogu}nost koristiti cjepivo
koje bi trebalo biti namijenjeno sveobuhvatnijoj za{titi u epi-
demiolo{kim situacijama gdje su cirkuliraju}i sojevi vrlo hetero-
geni u pogledu genskih i antigenskih osobina. Povijesna inte-
gracija znanja koju predstavlja 4CMenB }e se pokazati va`nom i
za razvoj drugih cjepiva u budu}nosti. 
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42]. Thus, for MenB vaccine development, sub-capsular
structures have been the choice as vaccine candidates [2,
3]. Several wild-type outer membrane vesicle (wtOMV)
vaccines have been successfully used to control clonal
MenB outbreaks [43, 44].
Progress in Meningococcal Vaccine
Development
A graphical representation of the development of
meningococcal vaccines with broad strain coverage can be
seen in Figure 1. Vaccines that use the capsular polysac-
charide as the target cover all organisms with the same
chemically and immunologically defined capsule, which
is generally designated as the serogroup. In contrast, pro-
tein-based vaccines against MenB consist of a combina-
tion of selected antigens that aim for broad strain coverage.
For decades, the "tailor-made" wtOMV vaccines against
particular outbreak strains were the only vaccines with
documented efficacy and effectiveness against MenB dis-
ease [2, 3, 45]. Vaccines based on the OMVconcept were
pioneered during the 1970s by Dr. Wendell D. Zollinger of
Walter Read Army Institute of Research, USA, Dr.
Torstein B. Helting of Behringwerke, Germany and Dr.
Carl E. Fraschof the US Food and Drug Administration,
USA and their coworkers [43, 46–51]. The research activi-
ty in these, and other laboratories, led to the development
of two vaccine formulations for clinical protection trials in
Cuba and Norway in the late 1980s [43]. Since they were
designed to target specific epidemic strains, there was no
expectation that they would be suitable for general use [43,
45, 52].
The initial wtOMV vaccine in general use was 
VA-MENGOCOC-BC®, developed at the Finlay Institute
in Cuba [53]. The second wtOMV formulation was
MenBvac®, developed at the Norwegian Institute of
Public Health (NIPH). Efficacy estimates of 83 % and
57 % were found for the Cuban and Norwegian trials in
adolescents, respectively [45, 53, 54]. The major differ-
ence between the efficacy estimates in the two trials was
due to a longer observation period for the Norwegian trial
(29 months versus 16 months in Cuba). Reanalysing the
Norwegian clinical data for a 10-month observation peri-
od, following a two-dose schedule, showed 87 % efficacy
[43, 45, 55]. A separate immunogenicity trial in Norway
confirmed that adding a booster dose about one year after
the primary immunization resulted in better persistence of
protective antibodies, thus potentially providing longer
lasting protection and greater effectiveness [43, 45,
55–57].
Two immunogenicity and reactogenicity trials [58, 59]
sponsored by the Ministry of Health in Iceland, the US
Centers for Disease Control and Prevention (CDC), the
World Health Organization (WHO) and the Pan-American
Health Organization (PAHO)compared the Cuban and
Norwegian wtOMV MenB vaccines. In the two studies
performed (one in Reykjavik, Iceland and the other in
Santiago, Chile), both vaccines induced good functional
immune responses as measured in a serum bactericidal ac-
tivity test, using human complement (hSBA) against the
respective, homologous MenB strains that were the basis
for the vaccines. Neither of the two vaccines gave a suffi-
ciently convincing immune response against heterologous
MenB strains (i.e. strains with a different PorA serosub-
type). When considering the MenB epidemic in Chile (on-
Figure 1. A dream coming through; in 2012 it became possible to prevent meningococcal disease caused by all major serogroups. (Note
that the first wtOMV vaccines against MenB disease came in 1988/89 giving mainly serosubtype specific protection.)
Slika 1. Ostvarenje sna; 2012. godine postalo je mogu}e sprije~iti meningokoknu bolest uzrokovanu naj~e{}im serogrupama
meningokoka (treba naglasiti da su prva wtOMV cjepiva protiv bolesti uzrokovane MenB iz 1988/89 pru`ala uglavnom za{titu
protiv odre|enih subtipova)
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going at that particular time), the monitoring committee
judged that neither of the wtOMV vaccines would impact
the local MenB clonal epidemic, especially not in infants,
because the causative organism was heterologous to both
vaccine strains. Immune responses to wtOMV vaccines in
infants are largely directed towards the PorA protein; only
about 10 % of infants mounted a protective antibody re-
sponse against the Chilean epidemic strain following vac-
cination with either the Cuban or Norwegian wtOMV vac-
cine [59]. In contrast, approximately half of adult vacci-
nees had a protective antibody response against the Chi-
lean epidemic strain after either of the two wtOMV vac-
cines, indicating broader immune response and thus, a less
restricted protection in this age group [59]. Reassuringly,
both wtOMV vaccines demonstrated good functional im-
munity; approximately 98 %, against their respective vac-
cine production strain in infants and older age groups,
which suggested that [43, 59] a protein based, "tailor-
made" vaccine for a defined clonal outbreak was likely to
be successful in all age groups [43, 60]. Another important
lesson from these pioneering clinical trials was that prima-
ry immunization with two doses of a wtOMV vaccineis
likely to be insufficient to maintain long term protection
against MenB disease [43, 45, 55].
Further Development and Use of 
"Tailor-Made" Vaccines
In 1991, a substantial clonal MenB outbreak was ac-
knowledged in New Zealand [61]. This outbreak was later
found to be caused by a strain with a PorA protein that was
heterologous to that in the Cuban and Norwegian wtOMV
vaccines. The magnitude and ongoing nature of this out-
break made it necessary to develop a new wtOMV vaccine
[61–64]. The MeNZB® vaccine, which was based on a typ-
ical isolate, strain NZ98/254, from the clonal outbreak in
New Zealand [65–69], was used between 2004 and 2008 to
limit the MenB epidemic. 
The experience from New Zealand is particularly im-
portant in the context of MenB vaccine development be-
cause extensive safety and effectiveness evaluations were
undertaken in more than one million vaccine recipients
[44]. In the present review, lessons learned during the de-
velopment and use of wtOMV vaccines and the significant
role that the experience played in the formulation of a mul-
ti-component MenB vaccine with broad strain coverage is
summarized. Particular emphasis should be given to the
history of MeNZB® where public health intervention was
used to fight the devastating MenB epidemic occurring in
New Zealand from the early 1990s to mid-2000s [44]. 
Since control of the epidemic was the primary objec-
tive of the MeNZB® program, vaccine effectiveness was
assessed in an observational manner. Initial effectiveness,
estimated using two different methodologies, was 80 %
(95 % CI 52.5–91.6 %) for children 6 months to less than 5
years of age [68] and 73 % (95 % CI 52–85 %) for all ages,
[68, 70–72]. However, since this was a large-scale intro-
duction rather than a clinical trial, interpretation of effec-
tiveness was complicated by secular disease trends. In an
analysis of disease prior to the vaccine campaign in 2004
showed a steady decrease in incidence between 2001 and
2004, which accelerated following implementation of the
vaccination program, indicating a vaccine effect [71].
Arnold and colleagues estimated overall vaccine effective-
ness using Poisson-regression models adjusted for year,
age, season, region, ethnicity and socioeconomic status
[71]. They also tested for a relationship between the num-
ber of doses and effectiveness, and for possible waning ef-
fectiveness one year after vaccination. Their approach al-
lowed the vaccine program effect to be differentiated from
a secular decrease in disease incidence. Arnold et al. esti-
mated vaccine effectiveness of 77 % (95 % CI 62–85 %)
over an average period of 3.2 years following the three-
dose primary series, but only 68 % when potential residual
confounding was considered. In partially vaccinated indi-
viduals, effectiveness was estimated to be 47 % (95 % CI
16–67 %) after two doses of MeNZB®. No evidence of
waning protection after one year with the full three-dose
Figure 2. Main Protein Composition of wtOMVs from
MenBvac® (44/76) and MeNZB® (NZ 98/254), visu-
alized by CBB staining after SDS-PAGE. (Please note
that Rmp and Opc is synonymous with "class 4" and
"class 5" proteins, respectively; indicated in Fig. 4.)
Slika 2. Proteinski sastav wtOMVs u MenBvac® (44/76) i
MeNZB® (NZ 98/254), prikazan bojanjem s CBB po-
mo}u SDS-PAGE (Rmp i Opc su sukladni proteinima
"klase 4" i "klase 5", kao {to je ozna~eno na Slici 4.)
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immunization series could be detected [71]. The adjust-
ments for residual confounding resulted from a test for
"protection" against pneumococcal disease by MeNZB®.
An observed dose-response relationship in the level of pro-
tection (not attributed to the vaccine itself) was interpreted
as a combination of program effects and some degree of
residual confounding [71]. The correlation of protection
with the number of doses further supports the conclusion
that the observed effectiveness is vaccine related.
Figure 3 illustrates the decline of the MenB disease
among the vaccinated and unvaccinated parts of the popu-
lation below 20 years of age in New Zealand. As can be
seen from the graph, the epidemic was on decline before
the vaccine campaign started. However, a significantly
more rapid decline was demonstrated among the vaccinat-
ed individuals. The effect of introducing the vaccine ap-
peared even more dramatic; analysing the cumulative cas-
es of meningococcal disease over the years from 2002 to
2010 in the Northern region (having the highest incidence,
and it was also here where the vaccination started).Within
a year the drop in meningococcal cases was significant and
by 2007 it was down to pre-epidemic rates in that region
[44].
It is worth noting that some protection was also ob-
served against MenB strains other than the outbreak clone
(i.e. non-P1.4) with an effectiveness of 54 % (41 % includ-
ing the correction for potential residual confounding).
Since the wtOMV component is not serogroup- (i.e. capsu-
lar polysaccharide) specific, effectiveness was also calcu-
lated against meningococcal disease caused by additional
serogroups where effectiveness was found to be 56 %, (or
43 % corrected for residual confounding) [71, 72]. These
observations are important when considering the role of
the New Zealand strain wtOMV in the new multi-compo-
nent vaccine 4CMenB. Another recent experience is the
regional use of MenBvac®, originally designed for Nor-
way, in the Normandy district in France [52, 73–76]. This
unique undertaking provided new data to expand the use of
the OMV concept [73].
Combining "Cutting-Edge" Technology with
Conventional Vaccinology
To provide broad strain coverage against the substan-
tial diversity of MenB organisms circulating worldwide,
vaccine candidates require well-conserved antigens and a
combination of multiple surface proteins, which can in-
duce bactericidal antibodies against a majority of circulat-
ing strains [77]. Inspired by whole genome sequencing of
Haemophilus influenzae in 1995 by Dr. J. Craig Venter and
colleagues at TIGR [78], Dr. Rino Rappuoli and the re-
search group at Chiron Vaccines in Siena (later Novartis
Vaccines) started on the endeavour of sequencing the
whole genome of one particular MenB strain (MC58).
From the digitally available genome there could be
searched for potential vaccine candidates in silico; clone
these proteins in E. coli and immunize mice, search for ex-
pression by flow cytometry and study the capacity of spe-
cific antibodies to kill meningococcus (bactericidal activi-
ty). This approach was called "reverse vaccinology" [79–
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Figure 3. Rates of Meningococcal B Disease in New Zealand. (Adopted from a Figure originally designed by Richard Arnold, New
Zealand; and presented in a slightly different format in [44])
Slika 3. Incidencija meningokokne bolesti grupe B u Novom Zelandu (preuzeta i djelomi~no promijenjena originalna slika autora
Richarda Arnolda, Novi Zeland [44])
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81]; this in contrast to the classical search for vaccine can-
didates where the investigation starts with specific anti-
bodies and/or the vaccine candidate itself. Through re-
verse vaccinology, the research team in Siena discovered a
number of new and previously unknown vaccine candi-
dates that, in only a few years, surpassed the efforts of con-
ventional vaccine research by the previous three decades
[82–85]. Initially, seven proteins were identified as pro-
mising vaccine candidates and later, a recombinant vac-
cine was formulated with three main active ingredients:
Neisserial adhesin A, (NadA), factor H-binding protein
(fHbp) and Neisserial heparin-binding antigen (NHBA)
[15, 86–88]. The two latter proteins were manufactured as
fusion proteins with genome-derived Neisserial antigen
(GNA) 2091 and GNA1030, respectively, to impart
greater stability and immunogenic properties [89]. The
three active components, NadA, fHbp, NHBA have been
identified as important virulence factors; NadA being an
adhesin, fHbp a lipoprotein binding the complement regu-
lating protein, human factor H, with substantial impor-
tance for survival of the bacteria in blood. Finally, NHBA
has demonstrated properties for binding heparin or highly
sulphated glycosaminoglycan analogues and other highly
negative charged biomolecules (anions). The full extent of
the pathophysiology of NHBA is under investigation.
Various studies have provided data showing importance
for adhesion and survival in the human bloodstream [90].
The whole story of vaccine development for 4CMenB has
been thoroughly described by Drs. Marzia M. Giuliani,
Mariagrazia Pizza and Davide Serruto in various publica-
tions [89, 91–93].
Early preclinical and clinical data for the properties
and performance of the three recombinant antigens
showed substantial promise. However, it became evident
that the strength and breath of immunogenicity could be
improved with the addition of OMVs [94, 95]. A formula-
tion where the recombinant proteins were combined with
OMVs from strain NZ 98/254 (the active ingredient in
MeNZB®, with PorA P1.4 as the immunodominant pro-
tein), performed much better than the recombinant pro-
teins alone [94, 95]. The choice with the addition of
MeNZB® was fortunate since this type of strain (cc41/44),
with fHbp-1.14 in general seems to be more difficult to kill
with antibodies raised by the recombinant proteins [89, 94,
95]. The reason for this is possibly due to a low degree of
expression and surface availability of the three antigens.
For fHbp some sophisticated studies illustrating this have
been done by the research group led by Dr. Dan M. Granoff
at CHORI, Oakland (CA), USA; showing that antibodies
raised against fHbp modular group I (for example fHbp-
1.1 as in the Novartis vaccine) are not very effective in
killing bacteria with fHbp modular group IV (for example
fHbp-1.14 or fHbp-1.55). This effect is most pronounced
when the strain tested in hSBA is a low or medium ex-
presser of fHbp [96, 97]. For the main components and for-
mulation of 4CMenB, Bexsero®; see Figure 4.
Figure 4. The Composition of 4CMenB, Bexsero®.Two recombinant fusion proteins and one single recombinant vaccine antigen
(NadA); the three main active components visualized red letters on a blue background. The forth active ingredient is the
wtOMV manufactured from the strain NZ 98/254 with PorA P1.4 as the immunodominant protein. The final vaccine is formu-
lated with Al-hydroxide as an adjuvant; making it a colloidal suspension.
Slika 4. Sastav cjepiva 4CMenB, Bexsero®. Dva rekombinantna fuzijska proteina i jedan rekombinantni cjepni antigen (NadA);
prikazane su tri glavne aktivne komponente uz ~etvrti aktivni sastojak wtOMV proizveden iz soja NZ 98/254 imunodomi-
nantnog proteina PorA P1.4. Cjepivo je napravljeno kao koloidna suspenzija dodatkom Al-hidroksida kao adjuvanta.
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The 4CMenB vaccine was granted Marketing Authori-
zation by the European Medicines Agency in January 2013
and later in Canada and Australia [87, 89, 91, 98]. In April
2014, 4CMenB received FDA Breakthrough Therapy des-
ignation in the US, and in June 2014 Novartis submitted an
application for 4CMenB to help protect US adolescents
and young adults [99, 100]. After MenB outbreaks at
Princeton University and University of California Santa
Barbara [101, 102], nearly 30,000 doses of Bexsero® were
distributed among students and staff under an
Investigational New Drug (IND) designation in the period
from December 2013 to April 2014 [100]. Estimates for
global strain coverage performed by the meningococcal
antigen typing system (MATS) for 4CMenB, vary from
about 70 % to over 90 %, depending on the regional epi-
demiologic situation [103], a substantial improvement
from the wtOMV vaccines (about 50 % in adults and less
than 10 % among infants against some heterologous
strains) [44, 59]. The recently developed method, MATS is
a way to measure the degree of total expression for each of
the three recombinant vaccine antigens (NadA, fHbp and
NHBA) and cross reactive variants of these proteins [104].
The MATS assay can be seen as a correlate to the well-es-
tablished bactericidal activity test with human comple-
ment (hSBA), that for a long time has been accepted as a
correlate of protection [23, 24, 105, 106]. How well
4CMenB really performs clinically and in real life awaits
practical use and prospective effectiveness studies. Of
note, MATS evaluation accounts separately for each indi-
vidual antigen, which eliminates any accounting for syner-
getic effects between antibodies against different antigens.
In some preclinical studies, such an effect has been shown
(cooperation between anti-fHbp and anti-NHBA antibod-
ies) [107, 108]. How these observations translate into clin-
ical performance of the 4CMenB among ordinary popula-
tion groups worldwide, only post-licensure evaluations
and implementation studies can tell.
Introducing a New Vaccine in Current
Childhood Immunization Programs
In developed countries, especially the UK, a MenB
vaccine has been high on the priority list since the control
of serogroups A, C, W and Y by conjugate vaccines [109,
110]. After decimation of MenC disease, 90 % of the cases
in the UK are MenB and this disease remains the last chal-
lenge in the area of meningococcus (as in most of the other
European countries). In the past 20 years, no other infec-
tious disease has claimed more lives than meningococcal
disease in the UK. Currently there are between 600 to
1,400 cases each year in England and Wales, generally in
infants less than 6 months of age [111]. Although 4CMenB
has the desired broad strain coverage, a substantial hesita-
tion to implement the vaccine in the routine childhood im-
munization has so far dominated the situation.
The precedence of using cost effectiveness studies
started with the introduction of pneumococcal conjugate
vaccines in the US, early in the 21st century [112]. In June
2013 the Joint Committee on Vaccination and Immun-
isation (JCVI) in UK presented a preliminary, non-favour-
able advice to the Ministry of Health of introducing the
4CMenB vaccine [113]. A number of doubts and problems
were presented, of which unfavourable cost-effectiveness
estimation was judged as the most important issue. This in-
terim JCVI recommendation started a large debate in
newspapers and scientific publications [112, 114–120].
Various aspects of the estimation were discussed, includ-
ing the role of economic evaluation in such decision
processes, the lack of sophistication for the cost-effective-
ness models per se and the relative accuracy of several pa-
rameters involved in the calculations. 
Various stakeholders were invited to submit more data
and arguments, which were evaluated and discussed by
JCVI in February 2014 [121]. Key points from the updated
recommendations are: introduction of 4CMenB in the
childhood immunization program with a "2+1" schedule at
2, 4 and 12 months. The vaccine is planned to be given to-
gether with the ordinary childhood vaccines. Infants who
have passed their 2 and 4 month visits will receive one
dose at 6 months and the booster dose at 12 months of age.
No other "catch-up" program will be offered [4, 122]. It is
important to note that a prerequisite for the proposed intro-
duction of 4CMenBmay be negotiations about the price
with the manufacturer. Involved parties are aiming for a
start of vaccination using 4CMenB by the autumn 2014
[111]. 
Important points to note include: 
i) Strain coverage is estimated to be 88 % for UK based
on the hSBA of 40 UK strains, not the 72 % predicted
by MATS [103, 123], which is known to underestimate
strain coverage [123].
ii) Vaccine efficacy is defined to be 90 %, with duration of
18 months after the two primary immunizations and 36
months following the booster. Duration of 10 years
protection might be expected if the vaccine is to be
used among adolescents; however, only infants are in-
cluded in the current plan because of a lack of cost ef-
fectiveness in older persons.
iii) The issue of possible influence on carriage and herd
immunity is currently under discussion. A recent car-
riage study in UK by Dr. Robert Read et al. (Lancet
2014, in press) and data from the use of MenBvac® in
Normandy, France [76] suggest a possible impact.
Reliable carriage data and the true effect on herd im-
munity would require implementation of the vaccine in
the population, followed by specific studies and over-
all good surveillance.
iv) The current cost-effectiveness models were ques-
tioned, particularly the value of vaccines for serious
diseases with a fairly low incidence. It was decided to
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establish a working group for study of some of these
aspects in greater detail. 
Discussion
Over the past 50 years, our understanding has evolved
regarding the importance of MenB disease per se, the so-
cial impact of fear caused by the devastating effects of the
disease and the role of OMV vaccines in providing protec-
tion. We now know that wtOMV-based vaccines are most
effective when used against epidemics due to a homolo-
gous or clonal outbreak caused by bacteria carrying the
same PorA as present in the vaccine. When used against
endemic disease or outbreaks due to a number of different
strains, (a heterologous epidemiologic situation), the level
of effectiveness will generally be too low to rely on a con-
ventional wtOMV vaccine alone for protection. Multiple
doses of these vaccines are required for primary protection
and a booster dose is needed to assure long term protec-
tion, especially in those who receive an initial vaccine se-
ries as young infants.  
More than 6,000 cases and around 250 deaths were
caused by meningococcal disease in New Zealand be-
tween 1991 and 2006, with approximately 80 % of cases
due to the epidemic clone targeted by the MeNZB® vac-
cine [64, 124]. However, following the concerted efforts of
an extensive international and national collaboration, in-
cluding the WHO, Chiron and NIPH; a vaccine, the
MeNZB® was developed to control this specific outbreak.
A substantial national mobilization in New Zealand, in-
volving complex logistics, monitoring and various com-
munication exercises were successfully carried out to han-
dle the public health challenge represented by the particu-
lar meningococcal epidemic. The mass vaccination cam-
paign that started in July 2004 and ended in June 2006, tar-
geted the population below 20 years of age (approximately
1.2 million persons) resulted in a vaccine uptake of 81 %
[68, 70, 71]. It has been estimated for the period between
July 2004 and December 2008that 210 cases, six deaths
and 15–30 cases of severe sequelae were avoided thanks to
the MeNZB® vaccine [71].
The New Zealand epidemic was waning before and
during the roll-out of MeNZB®. However, the staggered
introduction of the vaccine enabled year-by-year compari-
son of rates in vaccinated and unvaccinated populations
that allowed estimating the effectiveness of the vaccine.
Simultaneous modeling of invasive pneumococcal disease
and the clonal outbreak strain of MenB disease suggests a
degree of residual confounding that reduces the effective-
ness estimate from 77 % to 68 % [71]. Following the (cu-
mulative) number of MenB cases in the area with the high-
est incidence in New Zealand (the northern region) from
2002 to 2010 also demonstrate the vaccine impact from
one year (2004) to the next (2005) [44]. There was also
found some evidence for (lesser) cross-protection against
other MenB strains [71]. This observation is consistent
with the findings of Dr. Jordan Tappero et al. in Santiago,
Chile were they found an age-dependent, but clear func-
tional immune response (hSBA) against non-vaccine type
strains [59]. 
The extensive general experience with wtOMV vac-
cines, and in particular thethorough evaluation of
MeNZB® in more than one million individuals, provides
vital information regarding the safety and acceptability of
wtOMV vaccines for widespread use. By the end of 2013
more than 80 million doses of the wtOMV vaccine type
have been administered worldwide [20, 125]. Although
these vaccines are moderately reactogenic, in New
Zealand local and systemic reactions such as fever were
common, but predictable and transient; moreover did not
interfere with widespread acceptance of vaccination. A
very effective education program to inform parents and re-
cipients regarding the nature of these events likely con-
tributed to the high levels of public acceptance of this vac-
cine.
Unlike MeNZB®, which was designed to provide pro-
tection against a clonal outbreak, 4CMenB was formulated
to provide protection against the majority of circulating
MenB strains, which enable it to be used for routine immu-
nization in various regions of the world. The three recom-
binant protein components, active in this vaccine, were
identified through a process called reverse vaccinology,
starting with the bacterial genome instead of microbial
pathogenicity factors inducing dominant immune respons-
es in convalescents. A multi-component vaccine approach
was considered necessary for MenB because of the labile
nature of the meningococcal genome, differences in pro-
tein sequences and surface expression among various
MenB strains for the proteins selected as vaccine antigens.
The intrinsic ability of the meningococcus to change both
through recombination and variability in the degree of sur-
face expression of proteins creates a situation in which any
single component vaccine, even if effective initially,
would likely become ineffective over time as meningococ-
cus could adapt and become resistant to that particular vac-
cine. A multi-component strategy severely reduces the
ability of the organism to circumvent all antibodies elicited
by the vaccine. Based on these observations and insights
the novel multi-component vaccine 4CMenB contains
four major active ingredients, including the same wtOMV
as used in MeNZB®. It is important to recognize that this is
a new class of vaccine, which has employed reverse vacci-
nology in the design of a vaccine against MenB disease
suitable for more general use.
Apart from the implications of the MeNZB® experi-
ence for newer OMV containing vaccines such as
4CMenB, the program also provides a number of other im-
portant broadly applicable public health lessons. Key fac-
tors that contributed to the success of the program were the
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willingness of New Zealand and international parties to
collaboratively support the goal of epidemic control.
Lengthy negotiations and discussions built trust and un-
derstanding between parties. Those leading the project
from the New Zealand government and Chiron Vaccines
were given enough autonomy to enable timely progress.
The overall process from recognition of the outbreak in
New Zealand, to the final implementation of the vaccine
program was much faster than the normal process of vac-
cine development and introduction. Despite this, it took
several years, and some critics have indicated the need to
act more expediently during similar situations in the future
[126]. One key lesson might be that all countries should be
prepared, with regulatory mechanisms already in place, to
anticipate the possible rapid evaluation and introduction of
a new vaccine? The recent H1N1 influenza pandemic is a
case in point, but this lesson might be especially relevant
for developing countries where new vaccines for malaria,
typhoid and other diseases for which no prior experience in
Europe or the US exists, will become available. Such situ-
ations will also require local oversight and evaluation, ac-
tive surveillance, adequate epidemiology and sufficient
strain characterizations. In Cuba, Norway and New
Zealand [45] the basis for using the concept of wtOMV
vaccines was the selection of a manufacturing strain that
matched the clone causing the epidemic. In each case, a
measured approach to vaccine evaluation and introduction
was undertaken. In considering approaches to any public
health emergency, there will always be a tension between
the need to introduce a new intervention quickly and the
need to ensure that the intervention is safe and effective.
The extent and success of the post-introduction evaluation
in New Zealand could provide the impetus to develop pro-
tocols for earlier introduction of interventions for public
health emergencies which are associated with contempo-
raneous evaluation, thus reducing the need for extensive,
time consuming pre-introduction evaluations. This will
most likely happen when the vaccine is of a type or form
about which much is already known. 
Learning Points 
A number of learning points can be extracted from the
long and challenging voyage towards a MenB vaccine
with broad strain coverage. These points might also be
used in other vaccine development programs in times to
come.
1. Recombinant proteins are often inferior immunogens
when compared to their native counterparts produced
by pathogenic bacteria. Thus, a strong need for better
adjuvants and/or more optimal ways of formulating
vaccines continues to exist.
2. Preclinical immunization procedures and screening
methods do not always translate 1:1 in the clinic (for
example, the proteins GNA1030 and GNA2091 that
early on were shown to induce functional immunity,
but later proved to contribute little to hSBA when sera
from clinical trials were tested).
3. Even minor outer membrane proteins that might not be
under strong immunological selection ("pressure")
may vary much more than originally anticipated (for
example, fHbp versus PorA; PorA has a long standing
reputation of being "hypervariable" and antibodies in-
duced by one fHbp variant do not cross-react as well as
hoped for. This effect seems to be most pronounced in
the case where the expression level is low to moderate
and the difference is fairly large between the fHbp vari-
ant in the vaccine and the one harboured by the target
strain used in the hSBA test).
4. For development of protein based bacterial vaccines,
one is likely to reduce the risk for "escape mutants" by
choosing the strategy of using a multicomponent vac-
cine; especially with a dynamic and adaptive organism
as N. meningitidis.
5. Thorough epidemiological surveillance and strain
characterization is essential on a global level. Access to
well-curated strain collections is paramount for proper
vaccine evaluation.
6. Proper and well justified evaluation and judgement of
the actual value of a vaccination program requires con-
tinuing scrutiny and improvement of the models used
for evaluating them.
7. It is a constant and growing need for a balanced and re-
spectful collaboration between private industry (as
vaccine developers) and various public, governmental
bodies (as responsible for disease surveillance, imple-
mentation of vaccination programs and vaccine evalu-
ation from the perspective of society). 
Conclusion
Meningococcal wtOMV vaccines have been employed
for decades and administered to millions of individuals.
These vaccines have been effective and documented a well
characterized and acceptable safety profile. The major
limitation of these wtOMV vaccines is that their immune
response provides protection mainly against strains that
are homologous (i.e. harbouring the same PorA, sero-sub-
type protein) to the outbreak strain used to develop the vac-
cine [45, 59]. This shortcoming has restricted the utility of
wtOMV vaccines to large ongoing epidemics, and public
health benefits have been limited due to the long delay in
formulation. To address these concerns and make manage-
ment of MenB disease a routine rather than an episodic
event, a multi-component vaccine (4CMenB), which in-
cludes the wtOMV used in MeNZB®, has recently been
designed for widespread use and coverage against multi-
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ple strains and diverse epidemiological situations globally
[86, 87, 89, 91, 98]. Thus, even novel technologies in this
field draw on previous experience with wtOMV vaccines.
Additional knowledge and experience for use of the
wtOMV concept can also be gleaned from the handling of
a localized clonal outbreak in Normandy, France [52, 73,
74] and from preclinical and clinical studies using so-
called native OMV vaccines; where the LPS has been ge-
netically detoxified (lpx1-mutants), avoiding the need for
detergent extraction and with over expressed vaccine anti-
gens naturally folded in the membrane [127–133]. These
different and promising vaccine approaches owe much to
the pioneering experiences gained by using wtOMV vac-
cines, and in particular such large scale public health inter-
ventions as the one that took place in New Zealand with the
MeNZB® vaccine.
The first universal MenB vaccine is about to be imple-
mented in UK and in the coming years the whole vaccine
community will learn numerous important lessons; also
applicable to development and use of other protein-based
bacterial vaccines against other diseases. How well
4CMenB will perform we do not know. Available data and
a number of years with clinical experience give substantial
hope for success. However, it is also evident that there are
still room for improvement. The present vaccine is unlike-
ly to protect against all circulating strains. Somewhere be-
tween 70 % and 90 % might be a reasonable guess for clin-
ical straincoverage. Real sustainability of the protection in
field situations and the true effect on carriage and herdim-
munity will be evaluated as more information is gathered.
The introduction of 4CMenB marks a paradigm shift in
vaccinology. It is the first protein-based vaccine against a
bacterial disease that does not depend on some sort of tox-
in neutralization. In years to come, a number of similar
vaccines will be implemented in various immunization
programs [134, 135]. Thus, lessons learnt from the pio-
neering achievement will be paramount for making need-
ed vaccines faster available to those who are in need.
The heated and extended discussion from the UK, fol-
lowing the interim JCVI decision from July 2013, brought
out important and thoughtful arguments and views. One
important example was Professor Steven Black's comment
on the use of cost-effectiveness analyses as a "gating crite-
ria" to decide which vaccines should be developed or rou-
tinely used; runs the risk of transforming vaccines into pri-
marily "a tool for achieving cost savings within the health
care system rather than a public health intervention target-
ing human suffering, death and disability" [112]. It is real-
istic to hope for an increased understanding of the true and
comprehensive value of vaccines and vaccination follow-
ing the recent debate in UK. From various initiatives it can
also be anticipated an increased refinement in various
models used for estimating cost effectiveness and a better
understanding of the limitations of such calculations.
Over the past 20 years, particularly in the UK, tremen-
dous amounts of effort and many resources have been
spent on improving outcomes from meningitis and septi-
caemia by the government, scientists and health profes-
sionals by raising awareness and promoting early recogni-
tion of disease in addition to developing rapid life-saving
procedures in hospitals. This great cooperative effort has
been important and has made a difference. However, it has
also become painfully evident that prevention by an effec-
tive vaccine is the only sustainable solution to the chal-
lenge posed by the devastating consequences of meningo-
coccal disease. Even in situations like the current low inci-
dence of MenB disease in countries like Norway and
Croatia one might very well argue that a good and safe vac-
cine should be used. A new "tool" in the fight against
meningococcal disease is now available and should be
used in the best possible way to prevent the maximum
amount of death and suffering in the future.
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